Frequently asked questions about the OncoguardTM Liver solution

Search a phrase in the box below (eg, “sample types” or “results”) or choose a question from the list below.


Open all questions Close all questions

About the OncoguardTM Liver test

My doctor has ordered an OncoguardTM Liver test. What is it?

How is the OncoguardTM Liver test performed?

What do I need to do to prepare for the OncoguardTM Liver test?

How is the OncoguardTM Liver test different than other tests to detect liver cancer?

How well does the OncoguardTM Liver test perform?

I was assigned Intersex at birth. Can I use the OncoguardTM Liver test?

Can I use the OncoguardTM Liver test if I am on hormone therapy for a gender transition?


How do I get results of the test?

What does a positive test result mean?

What does a negative test result mean?

What does an invalid test result mean?

What happens if I get an invalid test result?


How often do I need to get the OncoguardTM Liver test?

I got a reminder that it is time for me to get tested for liver cancer. What should I do?

Insurance & Billing

Is the OncoguardTM Liver test covered by insurance?

How much will I have to pay for the OncoguardTM Liver test?

What if I can’t afford to pay for the OncoguardTM Liver test?


If you have other questions about the OncoguardTM Liver solution, please ask your doctor or call us at 1-844-870-8870.

The term liver cancer is used to represent the most common form of liver cancer, hepatocellular carcinoma (HCC).

References: 1. Mayo_Clinic_Staff. Abdominal ultrasound Accessed 09/25, 2020. 2. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169-177. 3. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, Clinical Gastroenterology and Hepatology (2021), doi: https:// 4. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. The New England Journal of Medicine. 2014;370(14):1287-1297. 5. Habib ZA. Maternal serum alpha-feto-protein: its value in antenatal diagnosis of genetic disease and in obstetrical-gynaecological care. Acta Obstet Gynecol Scand Suppl. 1977;61:1-92.